Pharmacokinetics, efficacy and safety of glyburide for treatment of gestational diabetes mellitus
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Gestational diabetes mellitus (GDM) complicates 10% of all pregnancies and is defined as hyperglycemia first noted during pregnancy. Rates of GDM are rising and untreated GDM results in complications for both mother and fetus. GDM is often managed by diet and exercise but 30-40% of women will require pharmacological intervention. Insulin has traditionally been the treatment of choice but since 2007, glyburide, a second generation sulfonylurea has become the most prescribed medication for GDM. AREAS COVERED: This review will cover the pharmacokinetics, efficacy, and safety of glyburide for the management of GDM. EXPERT OPINION: Management of GDM is challenging secondary to the stringent glycemic goals that mimic the lower glucose levels in pregnancy. Glyburide is generally effective in treating hyperglycemia. However, several studies have raised safety concerns showing higher neonatal intensive care unit (NICU) admissions, higher rates of macrosomia, large for gestational age and pre-eclampsia in the mother. For this reason, insulin should be first-line therapy for GDM. In areas of limited resources where the self-monitoring needed for accurate insulin dosing is not possible, where access to refrigeration for insulin storage is not universal, or severe needle phobia then the benefits of glyburide (controlling hyperglycemia) outweighs the harm of NICU admissions and macrosomia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concentrations of glyburide in umbilical cord plasma are approximately 50-70% of maternal levels (76,77).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [77]
In the citing paper
“Furthermore, in separate RCTs, glyburide and metformin failed to provide adequate glycemic outcomes in 23% and 25-28% of participants with GDM, respectively (76,77).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [77]
In the citing paper
“Sulfonylureas are known to cross the placenta and have been associated with increased neonatal hypoglycemia.”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [77]
Citations
Cites
Boney, C. M., Verma, A., Tucker, R., & Vohr, B. R. (2005) · Pediatrics · doi:10.1542/peds.2004-1808 · Cited by 2,303
Gestational Diabetes and the Incidence of Type 2 Diabetes
Kim, C., Newton, K. M., & Knopp, R. H. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1862 · Cited by 2,276 · cited 5×
“With these facts in mind, this paper will review the pharmacokinetics (PK), efficacy, and safety of this medication for treatment of GDM.”
BackgroundInfluentialBanting lecture 1980: of pregnancy and progeny.
Freinkel, N. (1980) · Diabetes · doi:10.2337/diab.29.12.1023 · Cited by 1,366
Banting Lecture 1980. Of pregnancy and progeny
Freinkel, N. (1980) · Diabetes · doi:10.2337/diabetes.29.12.1023 · Cited by 1,366
Increasing Prevalence of Gestational Diabetes Mellitus
Ferrara, A. (2007) · Diabetes Care · doi:10.2337/dc07-s206 · Cited by 1,171 · cited 1×
“It complicates up to 10% of all pregnancies, and rates are rising in the setting of increasing maternal age, obesity, and family history of diabetes.[1] Untreated hyperglycemia during the first trimester of pregnancy is associated with structural malformations and miscarriage.”
BackgroundMaliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., & Schellens, J. H. M. (2001) · PubMed · Cited by 1,130
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 8×
“With these facts in mind, this paper will review the pharmacokinetics (PK), efficacy, and safety of this medication for treatment of GDM.”
MethodResultInfluentialClausen, T. D., Mathiesen, E. R., Hansen, T., Pedersen, O., Jensen, D. M., Lauenborg, J., & Damm, P. (2008) · Diabetes Care · doi:10.2337/dc07-1596 · Cited by 724
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010
Stark Casagrande, S., Fradkin, J. E., Saydah, S. H., Rust, K. F., & Cowie, C. C. (2013) · Diabetes Care · doi:10.2337/dc12-2258 · Cited by 719 · cited 1×
“Only about 50% of individuals with type 2 DM reach glucose goals defined as glycated hemoglobin <7% (average glucose 150 mg/dL).[49] There is an obvious alternative to glyburide and that is insulin therapy (see Table 2 for comparison).”
BackgroundWendland, E. M., Torloni, M. R., Falavigna, M., Trujillo, J., Dode, M. A., Campos, M. A., Duncan, B. B., & Schmidt, M. I. (2012) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-12-23 · Cited by 626 · cited 2×
“[1] Untreated hyperglycemia during the first trimester of pregnancy is associated with structural malformations and miscarriage.[2,3] During the second and third trimester, uncontrolled hyperglycemia leads to increased fetal size with the risk of macrosomia and associated obstetrical complications such as shoulder dys…”
BackgroundCarr, D. B., Utzschneider, K. M., Hull, R. L., Tong, J., Wallace, T. M., Kodama, K., Shofer, J. B., Heckbert, S. R., Boyko, E. J., Fujimoto, W. Y., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2482 · Cited by 350
Expression of members of the multidrug resistance protein family in human term placenta
St-Pierre, M. V., Serrano, M. A., Macias, R. I. R., Dubs, U., Hoechli, M., Lauper, U., Meier, P. J., & Marin, J. J. G. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.279.4.r1495 · Cited by 325
A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events
Gangji, A. S., Cukierman, T., Gerstein, H. C., Goldsmith, C. H., & Clase, C. M. (2007) · Diabetes Care · doi:10.2337/dc06-1789 · Cited by 308 · cited 1×
“85) [50] Insulin compared to glyburide: no increased risk RR 0.”
BackgroundLong-term outcomes in mothers diagnosed with gestational diabetes mellitus and their offspring
METZGER, B. E. (2007) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31815a61d6 · Cited by 297
Insignificant transfer of glyburide occurs across the human placenta
Elliott, B. D., Langer, O., Schenker, S., & Johnson, R. F. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90421-m · Cited by 260 · cited 3×
“25 ng/mL, whereas the earlier assays [18] had a limit of 10 ng/mL.”
BackgroundResultInfluentialHebert, M., Ma, X., Naraharisetti, S., Krudys, K., Umans, J., Hankins, G., Caritis, S., Miodovnik, M., Mattison, D., Unadkat, J., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.5 · Cited by 252 · cited 1×
“One study investigated the steady-state PK of glyburide in 40 women with GDM, 40 healthy pregnant women, and 26 nonpregnant women with type 2 diabetes.[20] The authors found that drug concentrations rose within 30–60 min of ingestion, peaked at 2–3 h, and returned to baseline values at 8 h.”
BackgroundGlucose Intolerance in Pregnancy and Postpartum Risk of Metabolic Syndrome in Young Women
Retnakaran, R., Qi, Y., Connelly, P. W., Sermer, M., Zinman, B., & Hanley, A. J. G. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1990 · Cited by 190 · cited 1×
“tions.[9,10] For most women with GDM, achievement of glycemic goals”
BackgroundCamelo Castillo, W., Boggess, K., Stürmer, T., Brookhart, M. A., Benjamin, D. K., & Jonsson Funk, M. (2015) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2015.74 · Cited by 177 · cited 1×
“This population-based cohort from a nationwide US employer-based insurance claims over a decade that exclusively looked at women with GDM and their newborns (type 1 and type 2 diabetes excluded, ages 15–45 years included).[46] They studied glyburide exposure in the 150 days prior to delivery.”
MethodJacobson, G. F., Ramos, G. A., Ching, J. Y., Kirby, R. S., Ferrara, A., & Field, D. R. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.03.018 · Cited by 177 · cited 6×
“In a retrospective study of a large managed care organization in northern California, women with GDM treated with glyburide (n = 236) were compared to insulin (n = 268) treatment after failing diet therapy.[37] Maternal and neonatal outcomes and complications were assessed.”
BackgroundMethodInfluentialPatterns of Glycemia in Normal Pregnancy
Hernandez, T. L., Friedman, J. E., Van Pelt, R. E., & Barbour, L. A. (2011) · Diabetes Care · doi:10.2337/dc11-0241 · Cited by 170
Transport of Glyburide by Placental ABC Transporters: Implications in Fetal Drug Exposure
Gedeon, C., Behravan, J., Koren, G., & Piquette‐Miller, M. (2006) · Placenta · doi:10.1016/j.placenta.2005.11.012 · Cited by 139 · cited 1×
“[26–28] Evidence of preferential transport of glyburide by BCRP and MRP3 came from a study in which cell lines overexpressed BCRP, PGP, MRP1, MRP2, and MRP3 and [(3)H]-glyburide transport was studied.[29] Cells were then exposed to inhibitors of these transport proteins.”
BackgroundPlacental Transporters Relevant to Drug Distribution across the Maternal-Fetal Interface
Ganapathy, V., Prasad, P. D., Ganapathy, M. E., & Leibach, F. H. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39087-1 · Cited by 134 · cited 1×
“) from the fetoplacental unit to the maternal circulation, resulting in fetal protection by decreasing exposure tometabolites in thematernal circulation.[24] While albumin is likely themajor factor limiting glyburide transport across the human placenta [25], the three proteins identified in fetoplacental transport are…”
BackgroundJiang, Y.-F., Chen, X.-Y., Ding, T., Wang, X.-F., Zhu, Z.-N., & Su, S.-W. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4403 · Cited by 124 · cited 2×
“, the meta-analysis [40] evaluating the efficacy and safety of OAD drugs for GDM, 457 glybur-”
BackgroundMethodPollex, E. K., Lubetsky, A., & Koren, G. (2008) · Placenta · doi:10.1016/j.placenta.2008.05.001 · Cited by 121 · cited 1×
“to both maternal and fetal circulation.[31] Nicardipine, a potent”
BackgroundChmait, R., Dinise, T., & Moore, T. (2004) · Journal of Perinatology · doi:10.1038/sj.jp.7211147 · Cited by 118 · cited 1×
“Another study attempting to answer the same question investigated 69 women with gestational diabetes and found that women who succeeded with glyburide therapy did not fail dietary therapy until after 30 weeks of gestation, had fasting sugars <110 mg/dL, and 1-h postprandial <140 mg/dL (sensitivity 98% and specificity…”
BackgroundCamelo Castillo, W., Boggess, K., Stürmer, T., Brookhart, M. A., Benjamin, D. K., & Jonsson Funk, M. (2014) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000285 · Cited by 118
Perfusion studies of glyburide transfer across the human placenta: Implications for fetal safety
Kraemer, J. M., Klein, J., Lubetsky, A., & Koren, G. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.12.005 · Cited by 117 · cited 1×
“vitro perfusion studies of human cotyledon in which glyburide was infused into both maternal and fetal circulation at 200 ng/ mL.[23] They found evidence of fetal to maternal transfer against the concentration gradient.”
BackgroundFunction of P-Glycoprotein Expressed in Placenta and Mole
Nakamura, Y., Ikeda, S.-I., Furukawa, T., Sumizawa, T., Tani, A., Akiyama, S., & Nagata, Y. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6855 · Cited by 117
Hypoglycemic Activity of Glyburide (Glibenclamide) Metabolites in Humans
Rydberg, T., Jönsson, A., Røder, M., & Melander, A. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.1026 · Cited by 112 · cited 1×
“[16] M1 and M2b are considered the major metabolites and are metabolically active with hypoglycemic effects via increased insulin secretion.[17] These metabolites are cleared by the kidney.”
BackgroundUse of glyburide for the treatment of gestational diabetes: the San Antonio experience
Conway, D. L., Gonzales, O., & Skiver, D. (2004) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050310001650725 · Cited by 112
Feldman, J. M. (1985) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1985.tb03404.x · Cited by 104 · cited 1×
“3 and is ionized in plasma.[14] These characteristics impact transplacental transfer.”
BackgroundAnjalakshi, C., Balaji, V., Balaji, M. S., & Seshiah, V. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.09.031 · Cited by 104 · cited 1×
“733).[39] In one of the more recent and largest meta-analysis by Jiang et al.”
BackgroundSafety of Glyburide for Gestational Diabetes: A Meta-Analysis of Pregnancy Outcomes
Moretti, M. E., Rezvani, M., & Koren, G. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k577 · Cited by 97 · cited 1×
“69).[43] EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY 695”
BackgroundGedeon, C., Anger, G. J., Piquette‐Miller, M., & Koren, G. (2007) · Placenta · doi:10.1016/j.placenta.2007.08.004 · Cited by 89 · cited 1×
“They found that when novobiocin, an inhibitor of BCRP, was used, there was an increase in intravesicular accumulation of [(3)H]-glyburide; this was not seen when inhibitors of PGP or MRP were used, indicating that BCRP was likely the responsible protein.[30] These findings were supported by another study looking at th…”
ResultGlyburide transport across the human placenta
Schwartz, R. A., Rosenn, B., Aleksa, K., & Koren, G. (2015) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000672 · Cited by 83 · cited 1×
“Transplacental transport of glyburide was confirmed in a prospective observational study in 19 women with GDM on glyburide therapy that measured glyburide levels in maternal and umbilical venous blood samples immediately after delivery.[21] This was analyzed in relationship to the last time and dose of glyburide.”
BackgroundGlyburide and fetal safety; transplacental pharmacokinetic considerations
Koren, G. (2001) · Reproductive Toxicology · doi:10.1016/s0890-6238(01)00122-8 · Cited by 82 · cited 1×
“in an attempt to determine any unique properties of glyburide.[19] When comparing the pKa of the four drugs, there was little appreciable difference.”
BackgroundYogev, Y., Ben-Haroush, A., Chen, R., Rosenn, B., Hod, M., & Langer, O. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000129239.82126.a1 · Cited by 82 · cited 1×
“[37] In a continuous glucose monitor (CGM) study, CGMs were worn for 72 consecutive hours on 82 women with GDM – 30 were insulin treated, 27 diet treated, and 25 treated with glyburide.[47] Asymptomatic hypoglycemia was defined as >30 min with a glucose value <50 mg/dL detected by CGM only without patient awareness.”
MethodFeig, D. S., Razzaq, A., Sykora, K., Hux, J. E., & Anderson, G. M. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1482 · Cited by 80 · cited 5×
“With these facts in mind, this paper will review the pharmacokinetics (PK), efficacy, and safety of this medication for treatment of GDM.”
BackgroundInfluentialCheng, Y. W., Chung, J. H., Block-Kurbisch, I., Inturrisi, M., & Caughey, A. B. (2012) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2011.580402 · Cited by 72 · cited 1×
“6%) were treated with insulin.[45] The authors noted an increased risk of large for gestational age (weight >4.”
BackgroundContributions of human cytochrome P450 enzymes to glyburide metabolism
Zhou, L., Naraharisetti, S. B., Liu, L., Wang, H., Lin, Y. S., Isoherranen, N., Unadkat, J. D., Hébert, M. F., & Mao, Q. (2010) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.706 · Cited by 69 · cited 1×
“studied the effect of various human CYP isoforms on in vitro metabolism of glyburide in human liver microsomes.[33] They found that CYP3A4 is the major enzyme involved in in vitro metabolism of glyburide.”
BackgroundPollex, E. K., Anger, G. J., Hutson, J. R., Koren, G., & Piquette‐Miller, M. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.030791 · Cited by 60 · cited 1×
“The authors found decreased affinity for BCRP-mediated glyburide efflux with the Q141 variant.[32] The importance of this finding is that mothers with the”
BackgroundEffect of human serum albumin on transplacental transfer of glyburide
Nanovskaya, T. N., Nekhayeva, I. A., Hankins, G. D. V., & Ahmed, M. S. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.05.019 · Cited by 57 · cited 1×
“[24] While albumin is likely themajor factor limiting glyburide transport across the human placenta [25], the three proteins identified in fetoplacental transport are P-glycoprotein (PGP) (ABCB1 gene product), multidrug resistance-associated protein 1 (MRP1; ABCC1 gene product), and the breast cancer resistance protei…”
BackgroundRamos, G. A., Jacobson, G. F., Kirby, R. S., Ching, J. Y., & Field, D. R. (2007) · Journal of Perinatology · doi:10.1038/sj.jp.7211683 · Cited by 44 · cited 1×
“This study investigated women treated with glyburide (n = 78) and compared them to women treated with insulin (n = 44) in the 2 years prior with regard to glycemic control and neonatal outcomes.[44] Sixteen percent of women treated with glyburide were switched to insulin, and these women tended to have higher fasting…”
ResultRavindran, S., Zharikova, O. L., Hill, R. A., Nanovskaya, T. N., Hankins, G. D. V., & Ahmed, M. S. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.08.024 · Cited by 44 · cited 2×
“One study aimed to identify the metabolites of glyburide formed by placental microsomes of human and nonhuman primate (baboon) and compare them to the metabolites formed by liver microsomes of both species.[16] In all four groups, six metabolites of glyburide were identified: M1, M2a, M2b, M3, M4, and M5.”
BackgroundResultIdentification of CYP3A7 for glyburide metabolism in human fetal livers
Shuster, D. L., Risler, L. J., Prasad, B., Calamia, J. C., Voellinger, J. L., Kelly, E. J., Unadkat, J. D., Hébert, M. F., Shen, D. D., Thummel, K. E., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.09.025 · Cited by 39 · cited 3×
“[16] In all four groups, six metabolites of glyburide were identified: M1, M2a, M2b, M3, M4, and M5.”
BackgroundInfluentialMirzamoradi, M., Heidar, Z., Faalpoor, Z., Naeiji, Z., & Jamali, R. (2015) · PubMed · Cited by 35
Ogunyemi, D. A., Fong, A., Rad, S., Fong, S., & Kjos, S. L. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03326.x · Cited by 33 · cited 1×
“5%).[12] Between 2000 and 2011, among US women with private health insurance, use of glyburide for GDM”
BackgroundAnger, G. J., & Piquette‐Miller, M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.165639 · Cited by 31 · cited 1×
“[35] Gestational diabetes was induced in pregnant rats with streptozotocin on gestational day 6.”
Jaber, L. A., Antal, E. J., Slaughter, R. L., & Welshman, I. R. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1300 · Cited by 29 · cited 3×
“This was described in 20 patients with type 2 diabetes who underwent 12 weeks of glyburide monotherapy with Sustacal tolerance testing.[15] Area under the curve (AUC)0→4 glucose during Sustacal tolerance testing decreased at week 0 (−3 ± 11%) to week 6 (−29 ± 13%) to week 12 (−26 ± 19%) (P = 0.”
BackgroundMethodInfluentialMyngheer, N., Allegaert, K., Hattersley, A., McDonald, T., Kramer, H., Ashcroft, F. M., Verhaeghe, J., Mathieu, C., & Casteels, K. (2014) · Diabetes Care · doi:10.2337/dc14-1247 · Cited by 24 · cited 1×
“[36] Glyburide doses for this condition are much higher than what is standardly used for GDM – this patient took 85–90 mg/day and maintained excellent glycemic control throughout her pregnancy.”
BackgroundIncreased Glyburide Clearance in the Pregnant Mouse Model
Zhou, L., Zhang, Y., Hébert, M. F., Unadkat, J. D., & Mao, Q. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.033837 · Cited by 20 · cited 1×
“01)) was blunted by CYP3A inhibition by ketoconazole.[34] One group has investigated whether excess plasma lipids compete with and buffer plasma protein binding of glyburide.”
Background
Research works printed but not linked: 2
- Maliepaard M, 2001, Cancer Res, 61, 3458
- Mirzamoradi M, 2015, Acta Med Iran, 53, 97
Cited by
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s014 · Cited by 381
15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s014 · Cited by 268
14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s014 · Cited by 265
“Concentrations of glyburide in umbilical cord plasma are approximately 70% of maternal levels (44,45).”
Background
Metadata
- Authors
- Malek, R., & Davis, S. N.
- Affiliations
- University of Maryland, Baltimore (US)
- University of Maryland Medical Center (US)
- Corresponding author
- Davis, Stephen N.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2016-05-23
- Volume
- 12
- Issue
- 6
- Pages
- 691-699
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2362195380
- Cited by
- 54
- References
- 50
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 10 · 2019: 3 · 2018: 6 · 2017: 2
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Metabolism & Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glibenclamide, gestational diabetes mellitus, sulfonylureas, pharmacokinetics, drug safety, glycemic control, neonatal intensive care admission, macrosomia, preeclampsia, insulin therapy, antidiabetic drugs
- MeSH terms
- Animals, Blood Glucose, Female, Glyburide, Humans, Hypoglycemic Agents, Infant, Newborn, Insulin, Intensive Care Units, Neonatal, Pregnancy, Diabetes, Gestational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.